GLP-1 Drugs and Muscle Loss: The Research on Lean Mass

As GLP-1-class drugs became widely used for weight management, a specific worry moved into the foreground: are people losing muscle along with fat? The concern is reasonable and worth taking seriously, but it has also been amplified beyond what the data clearly shows. This article walks through where the concern comes from, what body-composition measurements actually capture, and what more recent research suggests.

Where the Concern Comes From

The GLP-1 class includes semaglutide and the dual agonist tirzepatide, with the triple agonist retatrutide in late-stage trials. Our overview of the GLP-1 drug class covers how these compounds developed.

Trials of these drugs that included body-composition scans reported that a portion of the total weight lost was lean mass, in some analyses roughly a quarter to a third. Taken at face value, that sounds alarming. But the headline figure needs unpacking, because the way lean mass is measured changes what the number means.

What “Lean Mass” Actually Measures

This is the most important and most often skipped point. When a study reports “lean mass,” it usually means everything in the body that is not fat: skeletal muscle, yes, but also water, blood, the liver and other organs, skin, and connective tissue. Skeletal muscle is only one component of that total.

This matters because it means a high percentage of lean-mass loss does not automatically translate into the same percentage of muscle loss. A person carrying excess weight also carries more total body water and a larger liver; some of the lean-mass reduction during weight loss reflects those tissues returning toward normal, not muscle wasting. Research in 2026 examining this directly found that loss of liver mass can exceed the change in muscle mass during GLP-1 weight loss. Interpreting a lean-mass figure as a muscle figure overstates the problem.

What Newer Research Suggests

Through 2025 and into 2026, the picture became more reassuring rather than less. Several analyses and reviews concluded that the majority of weight lost on GLP-1-class drugs is fat, and that the loss of functional muscle is smaller than early commentary implied. One line of research found that after several months the reduction in lean body mass was modest, while reductions in fat mass and in visceral adipose tissue, the metabolically harmful fat around the organs, were large.

This does not mean lean-mass loss is zero or irrelevant. It means the proportion attributable to muscle, and the functional consequences of that loss, appear smaller than the raw lean-mass percentages suggested. The relevant question has shifted from “is muscle lost?” to “how much functional muscle is lost, for whom, and can it be minimized?”

Strategies Studied for Preserving Lean Mass

Two strategies have the most consistent support, and neither is specific to GLP-1 drugs; they apply to weight loss in general.

The first is protein intake. Research on weight loss broadly supports a higher protein intake, often cited in the range of at least 1.2 grams per kilogram of body weight per day, distributed across meals, to help retain muscle during an energy deficit. This is harder to achieve when appetite is strongly suppressed, which is exactly what these drugs do, so protein intake requires deliberate attention rather than being left to appetite.

The second is resistance training. Structured strength training provides the stimulus that signals the body to retain muscle tissue during weight loss. Combined with adequate protein, it is the best-established approach for shifting the composition of weight lost toward fat.

Separately, pharmaceutical developers are studying agents intended specifically to preserve or build muscle during weight loss, and newer GLP-1 therapies are being evaluated for the quality of weight loss, not only the quantity. That research is ongoing and not yet settled.

What This Means for Interpreting the Topic

This article is for educational and informational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, or prevent any condition. Always consult with a qualified healthcare professional before making health-related decisions. Clinical trial data referenced here is sourced from peer-reviewed publications and may not reflect the most current findings.